A profibrotic effect of plasminogen activator inhibitor type-1 (PAI-1) in the heart

Experimental Biology and Medicine

Volumn 234, Issue 3, 2009, Pages 246-254

  Zaman, A K M Tarikuz ^a   French, Christopher J ^a   Schneider, David J ^a   Sobel, Burton E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Echocardiography; Fibrinolysis; Fibrosis; Heart failure; Risk factors

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; CREATINE KINASE; EVANS BLUE;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE; BODY WEIGHT; CONTROLLED STUDY; GENE OVEREXPRESSION; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART LEFT VENTRICLE SIZE; HEART LEFT VENTRICLE VOLUME; HEART LEFT VENTRICLE WALL; HEART MUSCLE FIBROSIS; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; TISSUE LEVEL; ANIMAL; BLOOD; C57BL MOUSE; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; ENZYMOLOGY; FIBROSIS; HEART INFARCTION; HEART MUSCLE; HEART VENTRICLE; METABOLISM; ORGAN SIZE; PATHOLOGY; PATHOPHYSIOLOGY; TRANSGENIC MOUSE;

MUS;

ANIMALS; BLOOD PRESSURE; BODY WEIGHT; CREATINE KINASE; ECHOCARDIOGRAPHY, DOPPLER; EVANS BLUE; FIBROSIS; HEART VENTRICLES; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MYOCARDIAL INFARCTION; MYOCARDIUM; ORGAN SIZE; PLASMINOGEN ACTIVATOR INHIBITOR 1; VENTRICULAR FUNCTION, LEFT;

EID: 63349106607     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0811-RM-321     Document Type: Article

References (32)

1. Juhan-Vague I, Alessi MC, Mavri A, Morange PE. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular risk. J Thromb Haemost 1:1575-1579, 2003.[CrossRef] [Medline]
2. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel B. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 143:104-109, 1994.
3. Sobel BE, Schneider DJ, Lee Y-H, Pratley RE. Insulin resistance increases PAI-1 in the heart. Biochem Biophys Res Commun 346:102-107, 2006.[CrossRef][Medline]
4. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor beta as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 328:1592-1598, 1993.[Abstract/Free Full Text]
5. Eitzman DT, McCoy RD, Zheng X, Fay WP, Shen T, Ginsburg D, Simon RH. Bleomycininduced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 98:232-237, 1996.
6. Fogo AB. Renal fibrosis:not just PAI-1 in the sky. J Clin Invest 112:326-328, 2003.[CrossRef] [Medline]
7. Horrow JC, Van Riper DF, Strong MD, Brodsky I, Parmet JL. Hemostatic effects of tranexamic acid and desmopressin during cardiac surgery. Circulation 84:2063-2070, 1991. [Abstract/Free Full Text]
8. Kaikita K, Fogo AB, Ma L, Schoenhard JA, Brown NJ, Vaughan DE. Plasminogen activator inhibitor-1 deficiency prevents hypertension and vascular fibrosis in response to long-term nitric oxide synthase inhibition. Circulation 104:839-844, 2001. [Abstract/Free Full Text]
9. Lijnen HR. Pleiotropic functions of plasminogen activator inhibitor-1. J Thromb Haemost 3:35-45, 2005. [CrossRef][Medline]
10. Nagai N, DeMol M, Lijnen HR, Carmeliet P, Collen D. Role of plasminogen system components in focal cerebral ischemic infarction. A gene targeting and gene transfer study in mice. Circulation 99:2440-2444, 1999. [Abstract/Free Full Text]
11. Oda T, Jung YO, Kim HS, Cai X, Lopez-Guisa JM, Ikeda Y, Eddy AA. PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney Int 60:587-596, 2001. [CrossRef][Medline]
12. Oikawa T, Freeman M, Lo W, Vaughan DE, Fogo A. Modulation of plasminogen activator inhibitor-1 in vivo:a new mechanism for the anti-fibrotic effect of rennin-angiotensin inhibition. Kidney Int 51:164-172, 1997. [Medline]
13. Olman MA, Mackman N, Gladson CL, Moser KM, Loskutoff DJ. Changes in procoagulant and fibrinolytic gene expression during bleomycin-induced lung injury in the mouse. J Clin Invest 96:1621-1630, 1995. [Medline]
14. Tuan TL, Hwu P, Ho W, Yiu P, Chang R, Wysocki A, Benya PD. Adenoviral overexpression and small interfering RNA suppression demonstrate that plasminogen activator inhibitor-1 produces elevated collagen accumulation in normal and keloid fibroblasts. Am J Pathol 2008 Oct. 2 [Epub ahead of print].
15. Zaman AKMT, Fujii S, Sawa H, Goto D, Ishimori N, Watano K, Kaneko T, Furumoto T, Sugawara T, Sakuma I, Kitabatake A, Sobel BE. Angiotensin-converting enzyme inhibition attenuates hypofibrinolysis and reduces cardiac perivascular fibrosis in genetically obese diabetic mice. Circulation 103:3123-3128, 2001. [Abstract/Free Full Text]
16. Moriwaki H, Stempien-Otero A, Kremen M, Cozen AE, Dichek DA. Overexpression of urokinase by macrophages or deficiency of plasminogen activator inhibitor type 1 causes cardiac fibrosis in mice. Circ Res 95:637-644, 2004. [Abstract/Free Full Text]
17. Allessie M, Schotten U, Verheule S, Harkes E. Gene therapy for repair of cardiac fibrosis. A long way to Tipperary. Circulation 111:391-393, 2005. [Free Full Text]
18. Zaman AKMT, Fujii S, Goto D, Furumoto T, Mishima T, Nakai Y, Dong J, Imagawa S, Sobel BE, Kitabatake A. Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity. J Mol Cell Cardiol 37:525-535, 2004. [CrossRef][Medline]
19. Lijnen HR, Maquoi E, Morange P, Voros G, Van Hoef B, Kopp F, Collen D, Juhan-Vague I, Alessi MC. Nutritionally induced obesity is attenuated in transgenic mice overexpressing plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 23:78-84, 2003. [Abstract/Free Full Text]
20. Toyota E, Kawaguchi Y, Ogasawara Y, Watanabe N, Neishi Y, Kawamoto T, Okura H, Yoshida K. Novel rat model of ischemic cardiomyopathy induced by repetitive myocardial ischemia/reperfusion injury while conscious. Circ J 71:788-795, 2007. [CrossRef][Medline]
21. Kjekshus JK, Sobel BE. Depressed myocardial creatine phosphokinase activity following experimental myocardial infarction in rabbit. Circ Res 27:403-414, 1970. [Abstract/Free Full Text]
22. Maroko PR, Kjekshus JK, Sobel BE, Watanabe T, Covell JW, Ross J Jr, Braunwald E. Factors influencing infarct size following experimental coronary artery occlusions. Circulation 43:67-82, 1971. [Abstract/Free Full Text]
23. Roberts R, Henry PD, Sobel BE. An improved basis for enzymatic estimation of infarct size. Circulation 52:743-754, 1975. [Abstract/Free Full Text]
24. Rosalki SB. An improved procedure for serum creatine phosphokinase determination. J Lab Clin Med 69:696-705, 1967. [Medline]
25. Shell WE, Kjekshus JK, Sobel BE. Quantitative assessment of the extent of myocardial infarction in the conscious dog by means of analysis of serial changes in serum creatine phosphokinase activity. J Clin Invest 50:2614-2626, 1971. [Medline]
26. Shell WE, Lavelle JF, Covell JW, Sobel BE. Early estimation of myocardial damage in conscious dogs and patients with evolving acute myocardial infarction. J Clin Invest 52:2579-2590, 1973. [CrossRef][Medline]
27. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254, 1976. [CrossRef] [Medline]
28. Declerk PJ, Verstreken M, Collen D. Immunoassay of murine t-PA, uPA, and PAI-1 using monoclonal antibodies raised in gene-inactivated mice. Thromb Haemostas 74:1305-1309, 1995. [Medline]
29. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome:a study of 1500 patients with angina petoris:the ECAT Angina Pectoris Study Group. Arterioscler Thromb 13:1865-1873, 1993. [Abstract/Free Full Text]
30. Chen Y, Billadello JJ, Schneider DJ. Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol 20:2696-2701, 2000. [Abstract/Free Full Text]
31. Nordt TK, Sawa H, Fujii S, Bode C, Sobel BE. Augmentation of arterial endothelial cell expression of the plasminogen activator inhibitor type 1 (PAI-1) gene by proinsulin and insulin in vivo. J Mol Cell Cardiol 30:1535-1543, 1998. [CrossRef][Medline]
32. Schneider DJ, Sobel BE. Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 7:813-817, 1996. [Medline]